Background
Final analysis of the international, multicenter, phase III CLL6 RESIDUUM trial (ALLG/FILO), N=143. Population: chronic lymphocytic leukemia (CLL) patients with detectable residual disease (not MRD-negative) after first-line fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. Tests whether lenalidomide maintenance improves outcomes versus observation in this residual-disease population.
Results
Interventions and follow up: Arm A: Lenalidomide maintenance, oral daily dosing, for 2 years (n=71)
Arm B: Observation (n=72)
Primary endpoint: Time to disease progression or death from randomization
mFollow up: NR
Results: PFS: median 64.6 months (95% CI 47.7–NR) with lenalidomide vs 42.4 months (95% CI 32.3–61.6) with observation, P=.039
PFS benefit durability: persisted for 3 years after maintenance was stopped
MRD negativity: more patients achieved MRD negativity with lenalidomide, especially those completing ≥20 maintenance cycles (rate NR)
OS: no difference between arms
Arm B: Observation (n=72)
Primary endpoint: Time to disease progression or death from randomization
mFollow up: NR
Results: PFS: median 64.6 months (95% CI 47.7–NR) with lenalidomide vs 42.4 months (95% CI 32.3–61.6) with observation, P=.039
PFS benefit durability: persisted for 3 years after maintenance was stopped
MRD negativity: more patients achieved MRD negativity with lenalidomide, especially those completing ≥20 maintenance cycles (rate NR)
OS: no difference between arms
Adverse events
Hematologic: more cytopenias with lenalidomide
Infectious: more infections with lenalidomide
Gastrointestinal: more GI effects with lenalidomide
Second malignancy: no cases of acute lymphoblastic leukemia observed
Infectious: more infections with lenalidomide
Gastrointestinal: more GI effects with lenalidomide
Second malignancy: no cases of acute lymphoblastic leukemia observed
Conclusions
In CLL patients with residual disease after first-line FCR chemoimmunotherapy, 2 years of lenalidomide maintenance significantly prolonged PFS (64.6 vs 42.4 months, P=.039) and increased MRD-negativity conversion versus observation, with benefit persisting 3 years after stopping treatment, but without an overall survival difference and at the cost of more hematologic, infectious, and gastrointestinal toxicity.
Key Limitations
All patients received FCR induction, a chemoimmunotherapy backbone that has been largely supplanted by venetoclax- and BTK-inhibitor-based regimens as first-line CLL therapy under current NCCN/ESMO guidance; applicability of post-FCR maintenance data to patients treated with modern targeted first-line regimens is unknown. Modest sample size (n=143) accrued over a long period (2011-2018) relative to a rapidly evolving treatment landscape. No OS benefit despite the PFS gain, and MRD-negativity conversion rates are not fully quantified in the abstract. A companion ancillary analysis of this same trial reported a long-term detrimental effect of lenalidomide maintenance on health-related quality of life, an important trade-off against the PFS benefit. Lenalidomide in CLL carries a well-documented risk of tumor flare reaction, and higher doses have previously been associated with unacceptable toxicity in this disease.
Clinical Context
Lenalidomide is not FDA- or EMA-approved for CLL, and post-chemoimmunotherapy maintenance is not part of current NCCN or ESMO first-line CLL algorithms, which are now built around fixed-duration venetoclax-obinutuzumab or continuous BTK inhibitors. CLL6 RESIDUUM's final analysis provides proof-of-concept that maintenance therapy can deepen and prolong response in patients with residual disease after chemoimmunotherapy, but because FCR is now a minority first-line choice (reserved mainly for younger, IGHV-mutated, fit patients under some guidelines), this trial is unlikely to change practice directly; it is most relevant as rationale for exploring maintenance strategies after modern first-line induction.